4.3 Letter

Maximally tolerated versus minimally effective dose: the case of rituximab in multiple sclerosis

Related references

Note: Only part of the references are listed.
Article Clinical Neurology

Rituximab-Associated Progressive Multifocal Leukoencephalopathy in Rheumatoid Arthritis

David B. Clifford et al.

ARCHIVES OF NEUROLOGY (2011)

Article Clinical Neurology

Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial

Amit Bar-Or et al.

ANNALS OF NEUROLOGY (2008)

Article Medicine, General & Internal

B-cell depletion with Rituximab in relapsing-remitting multiple sclerosis

Stephen L. Hauser et al.

NEW ENGLAND JOURNAL OF MEDICINE (2008)